Choose a Drug ! Aciphex Acomplia Actos Acyclovir Allegra Alli Diet Drug Altace Ambien Amoxicillin Atenolol Ativan Augmentin Avandia Avapro Baclofen Bactrim Biaxin Celebrex Celexa Cephalexin Champix Cialis Cipro Claritin D Clomid Coreg Depakote Diflucan Dilantin Diovan Doxycycline Effexor XR Elavil Estradiol Flomax Flonase Fluoxetine Folic Acid Fosamax Glucophage Hydroxyzine Ibuprofen Imitrex Keflex Lamisil Lasix Levaquin Levitra Lexapro Lipitor Mobic Naproxen Neurontin Nexium Norvasc Omeprazole Paxil Plavix Premarin Prevacid Promethazine Propecia Proscar Protonix Reductil Reglan Remeron Risperdal Singulair Sonata Synthroid Tamiflu Topamax Trazodone Ultra "C" tabs Ultra "L" tabs Ultra "V" tabs Ultram Viagra Wellbutrin Xenical Zithromax Zocor Zoloft Zyban Zyprexa Zyrtec

September 2007 August 2007 July 2007 June 2007 May 2007 April 2007 March 2007 February 2007 January 2007 December 2006 November 2006 October 2006 September 2006 August 2006 July 2006 June 2006 May 2006 April 2006 March 2006 February 2006

Opt-in for Free Newsletter, special discount offers, drugs information & latest pharmacy news.

German Court Rebuffed Sanofi’s Challenge against Acomplia’s Non–Compensation

Sanofi-Aventis’s legal challenge against the German government's decision to categorize Acomplia as a non-reimbursable medicine has been rejected by the Social Affairs Court in Berlin, according to a company spokesman.

The court offered a synopsis of its ruling last week in a reply to the French drug maker’s request that the German government's verdict should be debarred.

The spokesman alleged that Sanofi now has four weeks time to make a final decision whether to appeal this verdict or not.

He further added that the same court is performing an in-depth evaluation of Sanofi's appeal against Acomplia's non-reimbursement. In January, the German ministry of health accepted the proposal of the German Federal Joint Committee to incorporate diet drug acomplia below the class of lifestyle treatment under section 34 of the 'social code'.

Sanofi argued that Acomplia must be sheltered by the state health insurance programme as it lends aid to lower the possibility of diabetes and heart disease, in addition to its proven help for weight loss.